These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32423520)

  • 21. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
    Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
    J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
    Schrauder MG; Brunel-Geuder L; Häberle L; Wunderle M; Hoyer J; Reis A; Schulz-Wendtland R; Beckmann MW; Lux MP
    Breast; 2017 Apr; 32():186-191. PubMed ID: 28214786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
    Müller D; Danner M; Rhiem K; Stollenwerk B; Engel C; Rasche L; Borsi L; Schmutzler R; Stock S
    Eur J Health Econ; 2018 Apr; 19(3):341-353. PubMed ID: 28382503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.
    Norum J; Hagen AI; Maehle L; Apold J; Burn J; Møller P
    Eur J Cancer; 2008 May; 44(7):963-71. PubMed ID: 18362067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
    Kwon JS; Daniels MS; Sun CC; Lu KH
    J Clin Oncol; 2010 Feb; 28(4):675-82. PubMed ID: 19841329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanding the criteria for BRCA mutation testing in breast cancer survivors.
    Kwon JS; Gutierrez-Barrera AM; Young D; Sun CC; Daniels MS; Lu KH; Arun B
    J Clin Oncol; 2010 Sep; 28(27):4214-20. PubMed ID: 20733129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations.
    Hallsson LR; Sroczynski G; Engel J; Siebert U
    BMC Cancer; 2023 Jun; 23(1):590. PubMed ID: 37365514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.
    Guo F; Adekanmbi V; Hsu CD; Berenson AB; Kuo YF; Shih YT
    JAMA Netw Open; 2024 Feb; 7(2):e2356078. PubMed ID: 38353949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    Sun L; Brentnall A; Patel S; Buist DSM; Bowles EJA; Evans DGR; Eccles D; Hopper J; Li S; Southey M; Duffy S; Cuzick J; Dos Santos Silva I; Miners A; Sadique Z; Yang L; Legood R; Manchanda R
    JAMA Oncol; 2019 Dec; 5(12):1718-1730. PubMed ID: 31580391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    Cragun D; Weidner A; Lewis C; Bonner D; Kim J; Vadaparampil ST; Pal T
    Cancer; 2017 Jul; 123(13):2497-2505. PubMed ID: 28182268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
    Lim KK; Yoon SY; Mohd Taib NA; Shabaruddin FH; Dahlui M; Woo YL; Thong MK; Teo SH; Chaiyakunapruk N
    Appl Health Econ Health Policy; 2018 Jun; 16(3):395-406. PubMed ID: 29572724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel.
    Michaan N; Leshno M; Safra T; Sonnenblick A; Laskov I; Grisaru D
    Cancer Prev Res (Phila); 2021 Apr; 14(4):455-462. PubMed ID: 33355193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers.
    Petelin L; Hossack L; Shanahan M; Mitchell G; Liew D; James PA; Trainer AH
    Genet Med; 2020 May; 22(5):831-839. PubMed ID: 31996782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uptake and efficacy of bilateral risk reducing surgery in unaffected female
    Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG
    J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
    Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
    Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    Long J; Evans TG; Bailey D; Lewis MH; Gower-Thomas K; Murray A
    Breast J; 2018 Jul; 24(4):580-585. PubMed ID: 29286205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs and benefits of diagnosing familial breast cancer.
    Heimdal K; Maehle L; Møller P
    Dis Markers; 1999 Oct; 15(1-3):167-73. PubMed ID: 10595273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
    Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
    Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.